GATA2 and acute myeloid leukemia: In our specific case, the patient was informed about the elevated risk of progression in GATA2-related MDS or AML, the less favorable prognosis of HSCT in advanced disease compared to RCC, and the current lack of a clear indication for HSCT, given the uncertainty surrounding ASXL1 as an indicator of evolution.